Avraham Pharmaceuticals For Profit

Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease, supporting the development of its lead product candidate, ladostigil.

Estimated Revenue: $5 million
Funding Status: N/A
Industry: NeuroTech
Number Of Exists: N/A
Technology: Neuropharmacology
Founded Date: 2010-01-01
Investor Type: N/A
Headquarters: Yavneh, HaMerkaz, Israel
Employee Number: 11-50
Investment Stage: N/A